ESG resources

We report on a wide range of ESG data in our ESG Performance Report. We also report a number of additional disclosures below.

Latest reports

The ESG Performance Report includes our performance across our six environmental, social and governance (ESG) priority areas, and includes ESG data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2022.

Our position on

Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.

Policy positions

ESG reports archive

Search our archive of responsible business reports and resources dating back to 2002.


ESG Reports Archive

ESG ratings performance 

Detailed below is how we perform in key ESG ratings.

External benchmarking Current rating
Previous rating
Relative to peers
S&P Global Corporate Sustainability Assessment 86/100 88/100 2nd in the pharmaceutical industry group
Access to Medicines Index 4.06 4.23 1st in the Index
Antimicrobial Resistance Benchmark 84% 86% Leader
CDP Climate change A- A-  
CDP Water security B B  
CDP Forests (palm oil) A B  
CDP Forests (timber) B B  
CDP Supplier engagement rating Leader Leader  
Sustainalytics 18.8 Low risk rating 18.9 Low risk rating 3/473 subindustry group. A lower score represents lower risk.
Moody's ESG solutions 61 61 2nd in the pharmaceutical sector
ISS Corporate Rating B+ B  
FTSE4Good Member of FTSE4Good Index since 2004 Member of FTSE4Good Index since 2004  

Scores as at 2 March 2023


Charitable grants

We publish our charitable giving data in our Annual Report and ESG performance summary each year. We are further increasing transparency by publishing details of our individual charitable grants over £10,000 ($15,000). Details of the grants are available in the Charitable Grants report 2022 (PDF 417.1KB).

In addition to the grants of £10,000 or more declared here, GSK discloses grants to US-based non-profit organisations that foster increased understanding of scientific, clinical, and healthcare issues and contribute to improving patient care.


Back to top

Trade association memberships

GSK is a member of many trade and industry associations that primarily represent pharmaceutical, consumer products and vaccine businesses at the national, regional and international levels. 

Trade Association Membership 2022 (PDF - 100.8KB)
Back to top

Patient organisation funding

Patient organisations – non-profit organisations founded by patients, care-givers, family members and health professionals – are important stakeholders for GSK. 

They engage with healthcare providers, governments, the media, and patients to promote improved treatment and services for patients. They also campaign on issues that affect patients’ and care-givers’ lives, including increasing access to quality medicines, services and information on disease. Some carry out research into the causes of and potential treatments for specific conditions.

Listed below are the patient organisations that we support:


1. Pan European
During 2019-2021, we provided financial support to the following pan European patient organisations:

Agora (PDF-48.1KB)

Alzheimer Europe (PDF-194KB)

EUROPA DONNA - The European Breast Cancer Coalition (PDF-343KB)

European Cancer Patient Coalition (ECPC) (PDF-206KB)

European Federation of Allergy and Airways Disease Patients Association (PDF-677KB)

European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) (PDF-210KB)

European Patients' Forum (EPF) (PDF-196KB)

Lupus Europe (PDF-209KB)

Myeloma Patients Europe (PDF-257KB)

Pulmonary Hypertension Association Europe (PDF-55.9KB)

Sarcoma Patients EuroNet (SPAEN) (PDF-343KB)


2. National European
Details of funding provided to patient organisations across Europe can be found on the relevant market website. Where no market website currently exists, and for those GSK local operating companies that supported patient organisations in 2021, the information is either published directly on this page or in a booklet available from the local office.

Markets with websites:






The Netherlands





Markets without websites:


BeLux (PDF-344KB)



Czech Republic (PDF-113KB)


Hungary (PDF-85.1KB)

Ireland (PDF-129.9KB)

Israel (PDF-234KB)

Latvia (PDF-148KB)

Lithuania (PDF-129KB)


Romania (PDF-101KB)


Slovakia (PDF-121KB)

Slovenia (PDF-147KB)



Ukraine (PDF-104KB)

During 2021, we provided support to the following UK patient organisations:

Asthma UK and British Lung Foundation Partnership (PDF-206KB)

Blood Cancer UK (PDF-203KB)

Cancer52 (PDF-199KB)

Croydon Vision (PDF-202KB)

Fifth sense (PDF-202 KB)

Meningitis Now (PDF-202KB)


Myeloma UK (PDF-204KB)

Ovacome (PDF-202KB)

Ovarian Cancer Action (PDF-200KB)


Peaches (PDF-390KB)

Plasma of Hope (PDF-3.94MB)

Positive East (PDF-199KB)

Somerset and Wessex Eating Disorder Association (PDF-202KB)

Target Ovarian Cancer (PDF-203KB)

Youth@Heart (PDF-3.94MB)


During 2020, we provided support to the following UK patient organisations:

PAG disclosure 2020 (PDF-627KB)

During 2019, we provided support to the following UK patient organisations:

PAG disclosure 2019 (PDF-675KB)

GSK also provides funding to support UK community healthcare charities through the GSK IMPACT Awards, in partnership with The King’s Fund.  This annual programme recognises and promotes excellence in community healthcare, providing funding and training to help strengthen the award winners’ current management plans and support their future aspirations.


3. Emerging Markets and Intercontinental
During 2021 we provided funding to the following emerging markets and intercontinental patient organisations:

Markets with websites:




South Korea



Markets without websites:

Argentina (PDF-557KB)

Colombia (PDF-220KB)

Chile (PDF-227KB)

Hong Kong (PDF-269KB)

New Zealand (PDF-217KB)

Taiwan (PDF-244KB)


4. Global
During 2019-2021, we provided financial support to the following global patient organisations:

Global Asthma and Allergy Patient Platform (GAAPP) (PDF-218KB)

International Alliance of Patient Organisations (IAPO) (PDF-210KB)

International Gynecologic Cancer Society (IGCS) (PDF-210KB)

International Myeloma Foundation (IMF) (PDF-264KB)

Meningitis Research Foundation (MRF) (PDF-212KB)

World Hepatitis Alliance (WHA) (PDF-392KB)

World Ovarian Cancer Coalition (WOCC) (PDF-213KB)

Back to top

Engaging with healthcare professionals

We are committed to disclosing the payments we make, as we work together with healthcare professionals. Find our disclosure reports at Engaging with healthcare professionals.

Back to top

Back to top